Bernard Maybury
@lymphomule
🎧 In our latest podcast, Prof. Christopher Fox, Dr. Sridhar Chaganti, and Dr. Bernard Maybury discuss the 2025 guideline on managing relapsed or refractory large B-cell lymphoma b-s-h.org.uk/guidelines/gui…
I was going to tweet about this work at just published in @BrJHaem but @richardbuka got there first. A great 🧵
1/ Pleased to have been involved in this study in @BrJHaem that looks at secondary & idiopathic polycythaemia. This is not a fashionable area but a big deal that takes up a lot of time in the clinic. We looked at management and thrombosis rates in two large centres in England.
1/ Pleased to have been involved in this study in @BrJHaem that looks at secondary & idiopathic polycythaemia. This is not a fashionable area but a big deal that takes up a lot of time in the clinic. We looked at management and thrombosis rates in two large centres in England.
EVIDENCE OF SOMATIC EVOLUTION IN tRNA genes!!!! This finding could revolutionize what we know about cancer and somatic evolution in aging. Coming from the wizard of tRNA himself, Lluis Ribas, and genomeologist extraordinaire Fran Supek! biorxiv.org/content/10.110…
Just released BSH R/R LBCL guideline with updated guidance on this rapidly evolving field. onlinelibrary.wiley.com/doi/10.1111/bj…
So much change in R/R #DLBCL over recent years! See the updated @BritSocHaem guidelines now online onlinelibrary.wiley.com/doi/10.1111/bj…
Placebo trials of vaccines; it's amazing what you find when you look. @jakescottMD @AliSMV7 @DhandAbhay @alejodiaz81 @ThePharmFox Thus far, 94 RCTs of vaccines identified. Among them, 69 placebo controlled, and 4 control groups received nothing. So... bradspellberg.com/vaccine-rcts
Out now in the @BloodCancerJnl. Our study on risk factors and outcomes of CAR T manufacturing failure (MF) in LBCL. Led by Vaishali Dulobdas on behalf of the UK national CAR T panel @tobiasmenne2 @maeveannoreilly @AnneBlackPharm @sghorashian @KuhnlAndrea nature.com/articles/s4140…